Price$4.43-0.15 (-3.28%)
01:30 PM07:45 PM
News · 26 weeks41+33%
2026-04-192026-10-11
Mix2190d
- SEC Filings15(71%)
- Earnings4(19%)
- Other2(10%)
Latest news
25 items- SECSEC Form 425 filed by MiMedx Group Inc425 - MIMEDX GROUP, INC. (0001376339) (Filed by)
- SECSEC Form 8-K filed by MiMedx Group Inc8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
- PRMIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026MARIETTA, Ga., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, October 28, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13762954 A replay of the webcast will be available for approximately 30 days on the Company’s
- PRMIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification MatterCourt Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product Order Further Holds That Minimal-Manipulation Analysis Must Consider Tissue Characteristics Relevant to Reconstruction, Repair or Replacement in the Recipient MARIETTA, Ga., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that the U.S. District Court for the Northern District of Georgia issued a favorable ruling in the Company’s litigation challenging the U.S. Food and Drug Administration’s ("FDA") regulatory classification of AXIOFILL, the Company’s human placental-derived extracellular matrix particu
- PRMIMEDX to Participate in Upcoming Investor ConferencesMARIETTA, Ga., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the following investor conferences: Cantor Global Healthcare Conference | New York, NYWednesday, September 9, 20261:1 sessions Lake Street BIG10 Best Ideas Growth Conference | New York, NYThursday, September 10, 20261:1 sessions Investors interested in meeting with senior management at these events may contact their respective Cantor or Lake Street representative. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chr
- SECSEC Form EFFECT filed by MiMedx Group IncEFFECT - MIMEDX GROUP, INC. (0001376339) (Filer)
- SECSEC Form 424B3 filed by MiMedx Group Inc424B3 - MIMEDX GROUP, INC. (0001376339) (Filer)
- SECSEC Form 425 filed by MiMedx Group Inc425 - MIMEDX GROUP, INC. (0001376339) (Filed by)
- SECAmendment: MiMedx Group Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K/A - MIMEDX GROUP, INC. (0001376339) (Filer)
- SECSEC Form 425 filed by MiMedx Group Inc425 - MIMEDX GROUP, INC. (0001376339) (Filed by)
- SECSEC Form 425 filed by MiMedx Group Inc425 - MIMEDX GROUP, INC. (0001376339) (Filed by)
- SECSEC Form 425 filed by MiMedx Group Inc425 - MIMEDX GROUP, INC. (0001376339) (Filed by)
- SECSEC Form 425 filed by MiMedx Group Inc425 - MIMEDX GROUP, INC. (0001376339) (Filed by)
- SECSEC Form 425 filed by MiMedx Group Inc425 - MIMEDX GROUP, INC. (0001376339) (Filed by)
- SECMiMedx Group Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
- SECSEC Form 425 filed by MiMedx Group Inc425 - MIMEDX GROUP, INC. (0001376339) (Filed by)
- PRMIMEDX Announces Second Quarter 2026 Operating & Financial ResultsReports Second Quarter Net Sales of $64 Million Reiterates Full Year Financial Outlook on a Standalone Basis Announces Plans to Acquire Sanara MedTech Management to Host Conference Call Today, July 29, 2026, at 4:30 PM ET MARIETTA, Ga., July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the second quarter 2026. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "During the second quarter, we delivered another strong performance in our Surgical franchise, with 15% year-over-year revenue growth balanced across our sheet and particulate products. Our sustained momentum in several Su
- SECSEC Form 10-Q filed by MiMedx Group Inc10-Q - MIMEDX GROUP, INC. (0001376339) (Filer)
- SECMiMedx Group Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
- PRMIMEDX to Acquire Sanara MedTechTransformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX’s Strategic Priority to Expand Surgical Footprint, Nearly Doubling Surgical Revenue Immediately Accretive to Revenue Growth, Gross Margin and Adjusted EBITDA Margin Anticipates Over $20 Million in Run-Rate Cost Synergies Conference Call to Discuss Transaction Alongside MIMEDX’s Second Quarter 2026 Operating and Financial Results Today at 4:30pm EDT MARIETTA, Ga. and FORT WORTH, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") and Sanara MedTech Inc. ("Sanara," "Sanara MedTech") (NASDAQ:SMTI) today a
- PRMIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29MARIETTA, Ga., July 20, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, July 29, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13761338 A replay of the webcast will be available for approximately 30 days on the Company’s website
- INSIDERChief Financial Officer Doug Rice covered exercise/tax liability with 12,749 shares, decreasing direct ownership by 3% to 399,566 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERChief Commercial Officer Maersk-Moller Kimberly covered exercise/tax liability with 19,820 shares, decreasing direct ownership by 6% to 309,630 units (SEC Form 4) (withholding tax)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- SECMiMedx Group Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
- PRThe Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding ItIssued on behalf of Conexeu Sciences Inc. A new generation of tissue companies is betting that the future of wound care and reconstruction isn't a better patch — it's a material that helps the body regrow itself. One newly public name just took a concrete step toward proving it. NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — For most of medical history, the body's inability to regrow lost tissue has been treated as a fact to be managed rather than a problem to be solved. When skin, bone, or soft tissue is destroyed by injury, surgery, disease, or age, the standard of care has largely been about coverage and replacement — grafts, implants, fillers,
MDXG FAQ
6 questionsWhat does MiMedx Group Inc do?
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective...Where does MDXG stock trade?
MiMedx Group Inc (MDXG) is listed on NASDAQ.What sector and industry is MDXG in?
MiMedx Group Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about MDXG?
MiMedx Group Inc has had 7 recent analyst actions on file. The most recent action was from Citizens: Mkt Outperform with a $1000.00 price target on 2026-02-23. Recent price targets range from $700.00 to $2300.00.What companies are similar to MDXG?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MDXG side-by-side with any of them on Quantisnow.How can I track MDXG on Quantisnow?
Quantisnow aggregates MiMedx Group Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MDXG to receive live email and push alerts on every new disclosure.